



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/016,490
Source: O/PE
Date Processed by STIC: 5/21/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
- 2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. **EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)**
2. **U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202**
3. **Hand Carry directly to:**
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202**

Revised 01/29/2002

<1107
<1207
<1407
<1417
<1607

These mandatory numeric identifiers
do not use bold print
~~SEQUENCE LISTING~~

and
responses
need to
be shown
at the beginning of the Sequence Listing

10/016,490

in file. 200.
Does Not Comply
Corrected Diskette Needed.

[0132] The most specific SDSO sequences selected by the simplified selection method are presented as the following. Each sequence has been assigned by a sequence identifier.

<210> Sequence ID number: 1

<211> Length: 19

<212> Type ~~RNA/DNA~~ invalid. The only valid

<213> Organism: Artificial Sequence

<220> Feature:

<223> Other information:

<400> Sequence: 1

<410> Start and end points:

delete (542)tcagttacg gaaacgtgc (460) delete 19 ← insert

<210> Sequence ID number: 2

<211> Length: 19

<212> Type ~~RNA/DNA~~

<213> Organism: Artificial Sequence

<220> Feature:

<223> Other information:

<400> Sequence: 2

<410> Start and end points:

(315)gattat gcggtatcaaa cct (333)

19 ← insert the cumulative base total at the right margin of each line

19 ← insert

(sample of submitted file.) This is invalid format for a Sequence Listing. Please consult sample Sequence Listing (attached) for valid format. Also, please consult Sequence Rules

<110> Smith, John; - Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160>

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220>
<221> CDS
<222> (279)...(389)

<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1
agctcgatgc atatccgtgtt ccttccttcctt ctggggctttt caccctgtata atcagatetc 60
agggagagtg tcttgaccctt cctctgcctt tgcagtttca caggcaggca ggcaggcagc E 120
tgtatgtggca attgtgtggca gtgtccacagg cttttttagcc aggttttaggg tgggtttccgc 180
cgcggcgccgg cggcccccttc cgcgttttcctt tcggcgcttc ctttcgtttt ccttcgtttc 240

Please consult

Appendix 3, page 2

ggacctgatt aggtgagcaq gaggaggggg cagtttgc atg gtt tca atg ttc agc 296
 Met Val Ser Met Phe Ser
 1 10 15 20 25 30 35

tgg tct ttc aaa tgg cct gga ttt tgt ttg tct gtt tgt ttg ttc caa 344
 Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Cln
 10 15 20 25 30 35

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
 Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Cln Pro Asn Ser
 25 30 35

<210> 2
 <211> 37
 <212> PRT
 <213> Paramecium sp.

<<00> 2
 Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
 1 10 15

Phe Val Cys Leu Phe Cln Cys Pro Lys Val Leu Pro Cys His Ser Ser
 20 25 30

Leu Cln Pro Asn Leu
 35

<210> 3
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
 Met Val Asn Leu Glu Pro Met His Thr Glu Ile
 1 5 10

<210> 4
 <400> 4
 000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOS	Count includes total number of SEQ ID NOS	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.
		M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6
		M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids
		M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	use was used in sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or un- usual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is com- bined DNA/RNA
<300>	Publication Information	Leave blank after <300>	0
<301>	Authors	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials	✓ 0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm- dd, MMM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by data- base including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd
<313>	Relevant Residues	FROM (position) TO 0 (position)
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;